Melinta Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 290
- Market Cap
- -
- Website
- http://melinta.com
Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01966055
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT01811732
- Locations
- 🇺🇦
Melinta Investigational Site, Zaporizhzhia, Ukraine
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Single-Dose IV Oritavancin Diphosphate
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01784536
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01762839
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Phase 3
Completed
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- First Posted Date
- 2012-12-25
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT01756339
Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea
Phase 2
Completed
- Conditions
- Uncomplicated Urogenital Gonorrhea
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01591447
- Locations
- 🇺🇸
Jefferson County Department of Health, Birmingham, Alabama, United States
🇺🇸Harborview STD Clinic, Seattle, Washington, United States
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
Phase 2
Completed
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT01283581
- Locations
- 🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸Drug Research and Analysis Corp, Montgomery, Alabama, United States
🇺🇸Southbay Pharma Research, Buena Park, California, United States
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Phase 3
Completed
- Conditions
- Wound InfectionAbscessSystemic InflammationCellulitis
- Interventions
- Drug: Single-Dose IV Oritavancin Diphosphate
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 1019
- Registration Number
- NCT01252732
- Locations
- 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Phase 3
Completed
- Conditions
- Wound InfectionAbscessSystemic InflammationCellulitis
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 968
- Registration Number
- NCT01252719
- Locations
- 🇺🇸
Sharp Chula Vista Medical Center, Chula Vista, California, United States
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Phase 2
Completed
- Conditions
- Community-Acquired Bacterial Pneumonia
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT01168713